Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1/2 5Phase 3 3Phase 4 1

Status

Completed 63Terminated 18Recruiting 13Active not recruiting 13Unknown 9Withdrawn 7Not yet recruiting 5

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Other solid neoplasm 1CNS 1

Conditions

Unresectable Locally Advanced or Metastatic Solid Tumors 1Small Cell Lung Carcinoma 1SCLC, Extensive Stage 1Osteosarcoma 1Medulloblastoma 1Ependymoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Etoposide × Clear all
NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Shanghai JMT-Bio Inc.

Phase 1/2 Not yet recruiting
596 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07141771 2025-08-26

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
100 enrolled
Thoracic

SCLC, Extensive Stage

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06485908 2024-07-03

MEPENDAX

Assistance Publique Hopitaux De Marseille

Phase 1/2 Not yet recruiting
40 enrolled
CNS

Ependymoma, Medulloblastoma

NCT05590572 2022-10-21

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1/2 Not yet recruiting
148 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡